I-Mab (NASDAQ:IMAB) Stock Rating Upgraded by Brookline Capital Management

I-Mab (NASDAQ:IMAB) was upgraded by stock analysts at Brookline Capital Management to a “strong-buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

Separately, HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of I-Mab in a report on Friday, November 15th.

I-Mab Stock Up 2.9 %

I-Mab stock opened at $0.93 on Thursday. The company has a 50 day moving average price of $0.99 and a 200-day moving average price of $1.08. I-Mab has a fifty-two week low of $0.84 and a fifty-two week high of $2.00.

Institutional Investors Weigh In On I-Mab

Institutional investors have recently added to or reduced their stakes in the stock. Millennium Management LLC lifted its position in I-Mab by 763.1% during the fourth quarter. Millennium Management LLC now owns 97,749 shares of the company’s stock valued at $83,000 after acquiring an additional 86,424 shares during the last quarter. Cantor Fitzgerald L. P. purchased a new stake in shares of I-Mab during the 4th quarter valued at $119,000. BNP Paribas Financial Markets acquired a new stake in shares of I-Mab in the 4th quarter worth $93,000. XTX Topco Ltd grew its stake in I-Mab by 140.8% during the 3rd quarter. XTX Topco Ltd now owns 43,039 shares of the company’s stock worth $53,000 after buying an additional 25,163 shares during the last quarter. Finally, Garden State Investment Advisory Services LLC acquired a new position in I-Mab during the 3rd quarter valued at about $179,000. Institutional investors own 38.38% of the company’s stock.

I-Mab Company Profile

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.